M. Maas Enriquez

Peripheral deposition of α1‐protease inhibitor using commercial inhalation devices

G. Scheuch, P. Brand, K. Sommerer, 2003, European Respiratory Journal.

Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme

J. Oldenburg, J. Windyga, S. Lalezari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial

J. Oldenburg, K. Saxena, S. Lalezari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

I. Pabinger, S. Lalezari, M. Reding, 2018, Blood.

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

B. Ploeger, S. Mcleay, Anita Shah, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81‐8973, a full‐length recombinant factor VIII: results from an International comparative laboratory field study

Y. Katterle, S. Kitchen, H. Beckmann, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Chromogenic assay for BAY 81‐8973 potency assignment has no impact on clinical outcome or monitoring in patient samples

Y. Katterle, S. Kitchen, H. Beckmann, 2016, Journal of thrombosis and haemostasis : JTH.

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

C. Hermans, G. Di Minno, P. Holme, 2023, Therapeutic advances in hematology.